SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-23-020945
Filing Date
2023-04-27
Accepted
2023-04-27 16:17:06
Documents
21

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20007126x1_def14a.htm   iXBRL DEF 14A 1985213
6 logo_biocryst2a.jpg GRAPHIC 22227
7 ny20007126x1-pc_1.jpg GRAPHIC 817285
8 ny20007126x1-pc_2.jpg GRAPHIC 496396
9 ny20007126x1_barchart01.jpg GRAPHIC 159876
10 ny20007126x1_barchart02.jpg GRAPHIC 139969
11 ny20007126x1_barchart03.jpg GRAPHIC 151400
12 ny20007126x1_table01.jpg GRAPHIC 345705
  Complete submission text file 0001140361-23-020945.txt   8102125

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bcrx-20230613.xsd EX-101.SCH 5133
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE bcrx-20230613_def.xml EX-101.DEF 5528
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcrx-20230613_lab.xml EX-101.LAB 18048
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcrx-20230613_pre.xml EX-101.PRE 26795
15 EXTRACTED XBRL INSTANCE DOCUMENT ny20007126x1_def14a_htm.xml XML 189387
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-23186 | Film No.: 23857190
SIC: 2836 Biological Products, (No Diagnostic Substances)